Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial

被引：28

作者：

Araujo, John C.

Trudel, Geralyn C.

Saad, Fred

Armstrong, Andrew J.

Yu, Evan Y.

Bellmunt, Joaquim

Wilding, George

McCaffrey, John

Serrano, Sergio V.

Matveev, Vsevolod

Efstathiou, Eleni

Oudard, Stephane

Morris, Michael J.

Sizer, Bruce

Goebell, Peter J.

De Bono, Johann Sebastian

Paliwal, Prashni

Durham, Susan

Cheng, Shinta

Logothetis, Christopher

机构：

[1] Univ Washington, Seattle, WA 98195 USA

[2] Seattle Canc Care Alliance, Seattle, WA USA

[3] Univ Hosp Mar, IMIM, Barcelona, Spain

[4] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[5] ICORG, Dublin, Ireland

[6] Hosp Canc Barretos, Sao Paulo, Brazil

[7] NN Blokhin Canc Res Ctr, Moscow, Russia

[8] Univ Athens, Dept Clin Therapeut, Athens, Greece

[9] Georges Pompidou European Hosp, Dept Med Oncol, Paris, France

[10] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol Serv, New York, NY 10021 USA

[11] Essex Cty Hosp, Colchester, Essex, England

[12] Univ Erlangen Nurnberg, Dept Urol, D-91054 Erlangen, Germany

[13] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England

[14] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[15] Bristol Myers Squibb Co, Princeton, NJ USA

[16] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Onol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期

关键词：

D O I：

10.1200/jco.2013.31.6_suppl.lba8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA8

引用

页数：1

共 50 条

[21] Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial
Crabb, Simon J.
Griffiths, Gareth
Dunkley, Denise
Downs, Nichola
Ellis, Mary
Radford, Mike
Light, Michelle
Northey, Josh
Whitehead, Amy
Wilding, Sam
Birtle, Alison J.
Khoo, Vincent
Jones, Robert J.
EUROPEAN UROLOGY, 2022, 82 (05) : 512 - 515
[22] Predicting toxicity-related docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer (mCRPC) using open phase III trial data
Parikh, Anish B.
Martini, Alberto
Sfakianos, John
Galsky, Matt D.
Oh, William K.
Tsao, Che-Kai
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[23] Double-blind randomized trial of aflibercept versus placebo with docetaxel and prednisone for treatment of metastatic castration-resistant prostate cancer (mCRPC)
Tannock, Ian
Fizazi, Karim
Ivanov, Sergey
Thellenberg-Karlsson, Camilla
Flechon, Aude
Skoneczna, Iwona Anna
Orlandi, Francisco Jorquera
Gravis, Gwenaelle
Matveev, Vsevolod
Bavbek, Sevil E.
Gil, Thierry
Viana, Luciano S.
Aren, Osvaldo
Karyakin, Oleg
Elliott, Tony
Birtle, Alison J.
Magherini, Emmanuelle
Petrylak, Daniel Peter
Tombal, Bertrand
Rosenthal, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[24] Phase I trial of apalutamide plus abiraterone acetate, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
Molina, Ana
Christos, Paul
Hackett, Amy
Nordquist, Luke
Gelmann, Edward
Stein, Mark
Sternberg, Cora
Beltran, Himisha
Gracey, Lauren
Galletti, Giuseppe
Giannakakou, Paraskevi
Nanus, David M.
Tagawa, Scott T.
CANCER RESEARCH, 2019, 79 (13)
[25] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
Angelergues, A.
Bellmunt, J.
Efstathiou, E.
Gonzalez, I.
Gyftaki, R.
Delanoy, N.
Ozguroglu, M.
Flechon, A.
Guillot, A.
Le Moulec, S.
Castellano, D.
Esteban, E.
Munarriz, J.
Campos Balea, B.
Ardavanis, A.
Stefanou, D.
Oudard, S.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
[26] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Dorff, Tanya B.
Quinn, David, I
Pinski, Jacek K.
Goldkorn, Amir
Sadeghi, Sarmad
Tsao-Wei, Denice
Groshen, Susan
Kuhn, Peter
Gross, Mitchell E.
CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
[27] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
Oudard, Stephane
Fizazi, Karim
Sengelov, Lisa
Daugaard, Gedske
Saad, Fred
Hansen, Steinbjorn
Hjalm-Eriksson, Marie
Jassem, Jacek
Thiery-Vuillemin, Antoine
Caffo, Orazio
Castellano, Daniel
Mainwaring, Paul N.
Bernard, John
Shen, Liji
Chadjaa, Mustapha
Sartor, Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
[28] A prognostic model for predicting overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA) after docetaxel.
Chi, Kim N.
San Kheoh, Thian
Ryan, Charles J.
Molina, Arturo
Bellmunt, Joaquim
Vogelzang, Nicholas J.
Rathkopf, Dana E.
Fizazi, Karim
Kantoff, Philip W.
Li, Jinhui
De Bono, Johann Sebastian
Scher, Howard I.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[29] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
Kelly, W. K.
Halabi, S.
Carducci, M. A.
George, D. J.
Mahoney, J. F.
Stadler, W. M.
Morris, M. J.
Kantoff, P. W.
Monk, J. P., III
Small, E. J.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[30] Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Halabi, Susan
Dutta, Sandipan
Tangen, Catherine M.
Rosenthal, Mark
Petrylak, Daniel P.
Thompson, Ian M.
Chi, Kim N.
Araujo, John C.
Logothetis, Christopher
Quinn, David I.
Fizazi, Karim
Morris, Michael J.
Eisenberger, Mario A.
George, Daniel J.
De Bono, Johann S.
Higano, Celestia S.
Tannock, Ian F.
Small, Eric J.
Kelly, William Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) : 403 - +

← 1 2 3 4 5 →